drugset
drugset / Trial / NCT01559103

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103 ↗

Phase 1 Terminated 39 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindBasic science

Summary

Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients

Timeline

Start
2012-05-31
Primary completion
2014-02-28
Completion
2014-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziltivekimab Monoclonal antibody 30 mg Intravenous
Subject Ziltivekimab Monoclonal antibody 100 mg Intravenous
Subject Ziltivekimab Monoclonal antibody 300 mg Intravenous
Subject Ziltivekimab Monoclonal antibody 600 mg Intravenous

Indications

rheumatoid arthritis